New antiplatelet agents in the treatment of acute coronary syndromes

Archives of Cardiovascular Diseases

Volumn 107, Issue 3, 2014, Pages 178-187

  Sabouret, Pierre ^a   Taiel Sartral, Magali ^b  

^a Cardiovascular Prevention Institute   (France)

^b Cardiovascular Medical Unit   (France)

Author keywords

Antiplatelet drugs; Platelet reactivity

Indexed keywords

ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; PRASUGREL; TICAGRELOR; ADENOSINE; ADENOSINE PHOSPHATE; P2RY12 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; BLEEDING; GENETIC SCREENING; HUMAN; REVIEW; THROMBOCYTE FUNCTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COMPLICATION; CORONARY ARTERY BYPASS GRAFT; CORONARY THROMBOSIS; DIABETES MELLITUS; DRUG EFFECTS; HEMORRHAGE; KIDNEY FAILURE; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; PERSONALIZED MEDICINE; PHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; ADENOSINE MONOPHOSPHATE; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CORONARY ARTERY BYPASS; CORONARY THROMBOSIS; DIABETES COMPLICATIONS; HEMORRHAGE; HUMANS; INDIVIDUALIZED MEDICINE; MULTICENTER STUDIES AS TOPIC; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PURINERGIC P2Y12; RENAL INSUFFICIENCY; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84899465253     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2014.01.009     Document Type: Review

References (57)

1. J.L. Anderson, C.D. Adams, and E.M. Antman et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 116 2007 e148 e304
2. J. Silvain, J.P. Collet, and C. Nagaswami et al. Composition of coronary thrombus in acute myocardial infarction J Am Coll Cardiol 57 2011 1359 1367
3. J.L. Anderson, C.D. Adams, and E.M. Antman et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J Am Coll Cardiol 50 2007 e1 e157
4. Z.M. Chen, L.X. Jiang, and Y.P. Chen et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
5. K.A. Fox, S.R. Mehta, and R. Peters et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial Circulation 110 2004 1202 1208
6. C.W. Hamm, J.P. Bassand, and S. Agewall et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
7. P.T. O'Gara, F.G. Kushner, and D.D. Ascheim et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
8. P.G. Steg, S.K. James, and D. Atar et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
9. R.S. Wright, J.L. Anderson, and C.D. Adams et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 123 2011 2022 2060
10. J.M. Herbert, and P. Savi P2Y12, a new platelet ADP receptor, target of clopidogrel Semin Vasc Med 3 2003 113 122
11. P. Savi, J.M. Pereillo, and M.F. Uzabiaga et al. Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 2000 891 896
12. L. Bonello, L. Camoin-Jau, and S. Arques et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
13. D.J. Kereiakes, and P.A. Gurbel Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention JACC Cardiovasc Interv 1 2008 111 121
14. D. Sibbing, S. Braun, and T. Morath et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
15. F. Sofi, R. Marcucci, and A.M. Gori et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis Thromb Haemost 103 2010 841 848
16. M.S. Sabatine, C.P. Cannon, and C.M. Gibson et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
17. S.R. Mehta, J.P. Bassand, and S. Chrolavicius et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
18. J.T. Brandt, C.D. Payne, and S.D. Wiviott et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66e9 66e16
19. N.B. Norgard, and M. Abu-Fadel Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention Vasc Health Risk Manag 5 2009 873 882
20. J.P. Collet, J.S. Hulot, and A. Pena et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
21. J.L. Mega, S.L. Close, and S.D. Wiviott et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
22. M. Valgimigli, G. Campo, and M. Tebaldi et al. Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting J Thromb Haemost 8 2010 1903 1911
23. D. Alexopoulos, I. Xanthopoulou, and V. Gkizas et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
24. G. Montalescot, G. Sideris, and R. Cohen et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study Thromb Haemost 103 2010 213 223
25. D.J. Angiolillo, J.J. Badimon, and J.F. Saucedo et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial Eur Heart J 32 2011 838 846
26. S.D. Wiviott, D. Trenk, and A.L. Frelinger et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation 116 2007 2923 2932
27. S.D. Wiviott, E.M. Antman, and K.J. Winters et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial Circulation 111 2005 3366 3373
28. S.D. Wiviott, E. Braunwald, and C.H. McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
29. J.J. van Giezen, P. Berntsson, and H. Zachrisson et al. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis Thromb Res 124 2009 565 571
30. L. Wallentin P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use Eur Heart J 30 2009 1964 1977
31. D. Alexopoulos, G. Dimitropoulos, and P. Davlouros et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping JACC Cardiovasc Interv 4 2011 403 410
32. R.F. Storey, D.J. Angiolillo, and S.B. Patil et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
33. P.A. Gurbel, K.P. Bliden, and K. Butler et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
34. L. Wallentin, R.C. Becker, and A. Budaj et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
35. K.W. Mahaffey, D.M. Wojdyla, and K. Carroll et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 124 2011 544 554
36. S. James, A. Budaj, and P. Aylward et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 122 2010 1056 1067
37. D.L. Bhatt, A.M. Lincoff, and C.M. Gibson et al. Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
38. J. Huang, E.M. Driscoll, and M.L. Gonzales et al. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model J Pharmacol Exp Ther 295 2000 492 499
39. R.F. Storey, S. Husted, and R.A. Harrington et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 50 2007 1852 1856
40. R.A. Harrington, G.W. Stone, and S. McNulty et al. Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
41. K. Thygesen, J.S. Alpert, and H.D. White Universal definition of myocardial infarction J Am Coll Cardiol 50 2007 2173 2195
42. H.D. White, D.P. Chew, and H.L. Dauerman et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction Am Heart J 163 2012 182e4 190e4
43. D.L. Bhatt, G.W. Stone, and K.W. Mahaffey et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313
44. S. Leonardi, K.W. Mahaffey, and H.D. White et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial Am Heart J 163 2012 768e2 776e2
45. G. Montalescot, S.D. Wiviott, and E. Braunwald et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
46. S. James, D.J. Angiolillo, and J.H. Cornel et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial Eur Heart J 31 2010 3006 3016
47. M.T. Roe, and E.M. Ohman Prasugrel versus clopidogrel for acute coronary syndromes N Engl J Med 368 2013 188 189
48. S.K. James, M.T. Roe, and C.P. Cannon et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial BMJ 342 2011 d3527
49. M.T. Roe, P.W. Armstrong, and K.A. Fox et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 2012 1297 1309
50. E.M. Mahoney, K. Wang, and S.V. Arnold et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Circulation 121 2010 71 79
51. M. Kerneis, J. Silvain, and J. Abtan et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel JACC Cardiovasc Interv 6 2013 158 165
52. L. Bonello, U.S. Tantry, and R. Marcucci et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
53. S.A. O'Connor, J.S. Hulot, and J. Silvain et al. Pharmacogenetics of clopidogre Curr Pharm Des 18 2012 5309 5327
54. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
55. D. Trenk, G.W. Stone, and M. Gawaz et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
56. M.J. Price, P.B. Berger, and P.S. Teirstein et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
57. J.P. Collet, T. Cuisset, and G. Range et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109